Redeye: Medivir Q3 2024 - Next Step IND
Redeye comments on Medivir's Q3 report. We make changes to our base case as IGM Biosciences exits oncology, and a median time to progression of 10.9 months for fostrox has been established.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/